Akebia Therapeutics, Inc.
AKBA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$69,410 | -$51,925 | -$92,562 | -$282,024 |
| Dep. & Amort. | $37,504 | $41,846 | $37,697 | $36,128 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $7,775 | $9,317 | $17,849 | $0 |
| Change in WC | -$39,676 | -$20,727 | -$1,435 | -$105,611 |
| Other Non-Cash | $23,148 | -$1,895 | -$34,703 | $98,542 |
| Operating Cash Flow | -$40,659 | -$23,384 | -$73,154 | -$252,965 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$33 | $0 | -$114 | -$59 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | $0 | $0 | $0 | $0 |
| Inv. Sales/Matur. | $0 | $0 | $0 | $40,000 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | -$33 | $0 | -$114 | $39,941 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $7,901 | -$32,000 | -$33,000 | $44,783 |
| Stock Issued | $42,649 | $6,793 | $7,531 | $88,948 |
| Stock Repurch. | -$1,272 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $385 | $1 | $40,067 | $0 |
| Financing Cash Flow | $49,663 | -$25,206 | $14,598 | $133,731 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $8,971 | -$48,590 | -$58,670 | -$79,293 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $44,579 | $93,169 | $151,839 | $229,093 |
| End Cash | $53,550 | $44,579 | $93,169 | $149,800 |
| Free Cash Flow | -$40,692 | -$23,384 | -$73,268 | -$253,024 |